Holen Sie sich die Stockscreener-App
2.96
2.95%
-0.09
Handel nachbörslich:
3.28
0.32
+10.81%
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Trial to Highest Dose Cohort - HLTH
Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial - Moomoo
Anixa doses first patient in highest cohort of ovarian trial - Investing.com
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level. - Bitget
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PR Newswire
ANIXAnixa Biosciences Inc Revenue Breakdown - Finviz
Here's why you should add ANIX stock to your portfolio now - MSN
ANIX Assumed by D. Boral Capital -- Rating Maintained at Buy - GuruFocus
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
Anixa Biosciences secures Korean patent for breast cancer vaccine - Yahoo Finance
Anixa Biosciences Granted First Korean Patent for its Breast Can - GuruFocus
Anixa receives South Korean patent for breast cancer vaccine - Investing.com
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa receives South Korean patent for breast cancer vaccine By Investing.com - Investing.com South Africa
Anixa Secures Patent for Breast Cancer Vaccine in South Korea - Intellectia AI
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 - PR Newswire
Anixa Biosciences, Inc. Actuals & Estimates (NASDAQ:ANIX) - TradingView
Anixa Biosciences, Inc. Actuals & Estimates (DUS:CY71) - TradingView
Price to sales forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
Anixa presents breast cancer vaccine, ovarian CAR-T trial data - Investing.com UK
Anixa Biosciences (ANIX) Showcases Immunotherapy Progress at Key Symposium - GuruFocus
Anixa presents breast cancer vaccine, ovarian CAR-T trial data By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
Anixa Biosciences stock falls despite Phase 1 trial updates By Investing.com - Investing.com Nigeria
Anixa Biosciences stock falls despite Phase 1 trial updates - Investing.com
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium - Barchart.com
Enterprise value to EBIT forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
Price to earnings forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
ANIX Forecast — Price Target — Prediction for 2027 - TradingView
Anixa Biosciences, Inc. Actuals & Estimates (SWB:CY71) - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - The Globe and Mail
Anixa Biosciences, Inc. (ANIX) Latest Stock News & Headlines - Yahoo Finance
Anixa Biosciences Inc (ANIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
H.C. Wainwright Maintains Anixa Biosciences(ANIX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Penny Stocks To Watch For Growth In June 2026 - Sahm
Anixa Biosciences Inc (ANIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anixa Biosciences Inc (ANIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anixa Biosciences Inc (ANIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anixa Biosciences Inc (ANIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Anixa Biosciences Inc (ANIX) Institutional Confidence - TradingKey
Anixa Biosciences Inc (ANIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Anixa Biosciences Inc (ANIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anixa Biosciences Inc (ANIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi - GuruFocus
Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy - Stock Titan
Anixa Biosciences Gains Over 5% as Biotech Sector Shows Renewed Interest (ANIX)OBV Trend Line - newsline.com
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc - GuruFocus
Anixa Biosciences CEO Amit Kumar buys $52,500 in company stock By Investing.com - Investing.com India
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):